Phost'In Therapeutics
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours (NCT05495295) | Phost'In Therapeutics | 2022-07-18 |
Track Phost'In Therapeutics automatically
Every clearance here is in the API, with alerts when new ones post.